List of Excipients in Branded Drug CASODEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	CASODEX	bicalutamide	54868-4503	COPOVIDONE
Physicians Total Care Inc	CASODEX	bicalutamide	54868-4503	HYPROMELLOSES
Physicians Total Care Inc	CASODEX	bicalutamide	54868-4503	LACTOSE
Physicians Total Care Inc	CASODEX	bicalutamide	54868-4503	MAGNESIUM STEARATE
Physicians Total Care Inc	CASODEX	bicalutamide	54868-4503	POLYETHYLENE GLYCOL

Casodex Excipient Strategy and Commercial Opportunities for Bicalutamide

Last updated: August 15, 2026

Casodex is the branded formulation of bicalutamide, a nonsteroidal antiandrogen used primarily at 50 mg with LHRH analog therapy and at 150 mg as monotherapy in prostate cancer. Its commercial opportunity has shifted from brand protection to generic substitution, formulation differentiation, supply reliability, and lifecycle products. The core immediate-release tablet uses conventional excipients, leaving potential value in solubility enhancement, dosage-form convenience, and manufacturing optimization rather than in basic tablet replication.

What is Casodex and how is it formulated?

Casodex contains racemic bicalutamide, with the active R-enantiomer responsible for androgen-receptor antagonism. The marketed product is an oral, immediate-release, film-coated tablet available in 50 mg and 150 mg strengths in major markets. The U.S. label identifies the following inactive ingredients:

Component	Formulation role
Lactose monohydrate	Diluent and tablet bulking agent
Microcrystalline cellulose or equivalent compressible filler, where used by market	Tablet structure and compressibility
Povidone	Binder
Sodium starch glycolate	Disintegrant
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Titanium dioxide	Opacifier and coating pigment

The exact excipient list and quantitative composition can vary by jurisdiction and manufacturer. FDA-approved generic products should be evaluated through their individual prescribing information and abbreviated new drug application records rather than by assuming that they duplicate the branded formulation.

Bicalutamide is highly lipophilic and has low aqueous solubility. That property creates formulation sensitivity around particle size, wetting, granulation, dissolution, and exposure consistency. The immediate-release tablet is technically straightforward, but the active pharmaceutical ingredient remains suitable for formulation strategies that improve dissolution and dose administration.

What excipients are most important in a Casodex generic?

The principal excipient decisions concern powder flow, lubrication, disintegration, dissolution, and lactose compatibility.

Lactose and filler selection

Lactose is commercially attractive because it is inexpensive, widely available, and familiar to regulators. It can support direct compression or wet granulation depending on the grade and API loading. Potential limitations include lactose intolerance concerns, aldehyde-related compatibility risks with certain amine-containing APIs, and supply concentration among pharmaceutical-grade producers.

Bicalutamide does not require a high-dose tablet. A 50 mg strength allows substantial flexibility in selecting fillers and processing aids. A generic manufacturer can therefore pursue:

• Lactose-based tablets for cost efficiency.
• Lactose-free formulations using mannitol, microcrystalline cellulose, dibasic calcium phosphate, or starch-based fillers.
• Co-processed excipients to improve flow and content uniformity.
• Low-moisture formulations where API stability or dissolution is sensitive to water exposure.

A lactose-free product could support institutional purchasing and patients who avoid lactose-containing medicines, but the commercial advantage is likely incremental because lactose in a solid oral tablet is usually present at a low amount relative to dietary exposure.

Povidone and alternative binders

Povidone supports granule strength and reduces segregation during processing. Excessive binder concentration can slow disintegration or dissolution, which matters for a poorly soluble API. Alternatives include copovidone, hydroxypropyl cellulose, pregelatinized starch, and dry-binder grades of microcrystalline cellulose.

Dry granulation or roller compaction may reduce process water and shorten manufacturing time. Direct compression can reduce unit operations but requires strong control of particle-size distribution and blend uniformity. The optimal platform depends on the API crystal form, bulk density, flow properties, and target dissolution profile.

Sodium starch glycolate and superdisintegrants

Sodium starch glycolate is a conventional choice for rapid tablet breakup. Other options include crospovidone and croscarmellose sodium. Crospovidone may support rapid wicking with relatively limited swelling, while croscarmellose sodium can provide strong disintegration across a range of compression forces.

For bicalutamide, the disintegrant cannot be selected independently of the solubilization approach. A tablet may disintegrate rapidly while still producing slow API dissolution because the drug remains hydrophobic. The formulation target should therefore use dissolution data, not disintegration time alone.

Magnesium stearate and lubrication control

Magnesium stearate is standard for tablet lubrication but can form a hydrophobic film around particles when overmixed. That effect can reduce dissolution and create batch-to-batch variability. Commercially relevant process controls include:

• Limiting lubricant concentration.
• Controlling lubrication time and shear.
• Evaluating sodium stearyl fumarate as an alternative lubricant.
• Monitoring blend uniformity after lubricant addition.
• Linking tablet hardness and compression force to dissolution performance.

Lubrication is a low-cost but meaningful source of manufacturing differentiation because it can affect both scale-up robustness and comparative dissolution.

What formulations are protected or commercially differentiated for bicalutamide?

The standard immediate-release film-coated tablet has limited differentiation value unless a manufacturer obtains meaningful regulatory or market advantages. More promising platforms target administration, solubility, or combination therapy.

Solubility-enhanced bicalutamide

Potential technologies include:

• Nanocrystalline or micronized bicalutamide.
• Amorphous solid dispersions.
• Polymer-based solid dispersions using copovidone, hypromellose acetate succinate, or related polymers.
• Surfactant-containing formulations.
• Lipid-based systems.
• Cyclodextrin complexes.
• Co-crystals or alternative solid forms.

These approaches can increase dissolution and may reduce food-effect variability. They also create new development burdens, including physical stability, recrystallization risk, residual solvent control, bioequivalence, and analytical method development.

A solubility-enhanced formulation is commercially stronger when it produces a measurable benefit such as lower dose, reduced dosing frequency, improved fasting-state exposure, or easier administration. A formulation that only improves laboratory dissolution without a clinical or regulatory advantage may face limited pricing power against low-cost generics.

Orally disintegrating and dispersible tablets

An orally disintegrating tablet could address swallowing difficulty in an older prostate-cancer population. The principal excipient needs are a porous matrix, taste control, rapid wetting, and adequate mechanical strength. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavoring systems are common development tools.

Bicalutamide has a pharmacologically active dose of 50 mg or 150 mg, making a 150 mg orally disintegrating tablet more difficult to optimize than a low-dose ODT. Taste masking may also be necessary because rapid oral dispersion increases contact with taste receptors.

Fixed-dose combinations

The clearest lifecycle opportunity is a fixed-dose combination involving an androgen-deprivation therapy component. Commercial and regulatory feasibility is constrained because standard treatment commonly combines bicalutamide with an LHRH agonist or antagonist administered by a different route. A fixed oral combination would therefore require a suitable oral partner and a clinical rationale for co-packaging or co-formulation.

A co-packaged product may be easier than a single tablet because it avoids incompatibility and dose-ratio constraints. Its value would depend on treatment guidelines, payer acceptance, adherence data, and whether the partner drug is already available as an oral product.

Modified-release products

Modified release is a weaker opportunity for bicalutamide than immediate-release or solubility-enhanced delivery. Bicalutamide has a long terminal half-life, reported at approximately one week, and is dosed once daily. Extending release may not provide a strong clinical benefit and could complicate exposure control. A modified-release product would need a clear advantage over the existing once-daily regimen.

When did Casodex lose exclusivity and what is the generic status?

Casodex has lost the principal commercial exclusivity that supported the branded product. Bicalutamide generic tablets have been approved in the United States and other markets, and the active ingredient is generally treated as an established generic oncology product.

Milestone	Commercial implication
U.S. approval of Casodex	Established the branded bicalutamide reference product
Patent and regulatory exclusivity expiry	Opened the market to generic development
Approval of generic bicalutamide tablets	Shifted competition toward price, supply, and contracting
Current market stage	Mature generic market with limited conventional brand premium

The exact generic launch dates, ANDA approvals, and current marketing status vary by strength and jurisdiction. FDA Orange Book records should be checked for the relevant NDA and product strength because approval, discontinuation, and marketing-status entries can differ across 50 mg and 150 mg products.[1]

What is the Orange Book and Paragraph IV status of Casodex?

Casodex is associated with an older small-molecule NDA rather than a biologic reference product. Paragraph IV litigation was most relevant during the period when generic applicants challenged listed patents before broad generic entry. That litigation cycle is no longer the principal commercial barrier for standard bicalutamide tablets.

For current diligence, the relevant questions are:

1. Whether the brand NDA remains listed as marketed or discontinued.
2. Whether any patents remain listed against the reference product.
3. Whether the generic applicant made Paragraph IV, Paragraph III, or Section viii certifications.
4. Whether any approved formulation has unexpired method-of-use or formulation claims.
5. Whether the proposed generic is for 50 mg, 150 mg, or both strengths.

An applicant developing a conventional tablet generally faces a lower patent risk profile than an applicant using a new solid form, amorphous dispersion, nanoparticle system, or combination product. Those newer technologies can create their own patent estate but may also trigger freedom-to-operate issues around third-party excipient, process, or drug-delivery patents.

How strong is the bicalutamide patent estate?

The patent estate for the original bicalutamide product is materially weaker than the estate surrounding newer prostate-cancer therapies. Core composition-of-matter protection has expired in the principal commercial jurisdictions, and the product has been exposed to generic competition for many years.

The remaining IP considerations are more likely to involve:

• New crystalline or amorphous forms.
• Particle-size distributions.
• Solid dispersions.
• Nanoparticle manufacturing methods.
• Specific excipient ratios.
• Dissolution-controlled tablets.
• Orally disintegrating dosage forms.
• Combination products.
• Packaging and stability systems.
• Process patents covering continuous manufacturing or specialized granulation.

These claims are narrower than a composition-of-matter patent. Their commercial value depends on claim breadth, enablement, freedom to operate, enforceability, and whether the formulation is substitutable at the pharmacy level.

A formulation patent that claims a specific polymer, particle-size range, or excipient ratio may be avoidable through routine design-around. A patent tied to a clinically validated exposure advantage or a required solid form is more commercially relevant.

What commercial opportunities exist for Casodex excipients?

The most credible opportunities fall into four categories.

Cost-reduced generic manufacturing

A supplier can improve margins by reducing tablet weight, simplifying processing, increasing yield, or replacing expensive specialty excipients with standard pharmaceutical-grade materials. The strongest targets are:

• Direct-compression systems.
• Low-shear dry granulation.
• Co-processed filler-disintegrant systems.
• Reduced lubricant use.
• Improved film-coating efficiency.
• Larger-scale continuous manufacturing.

The product is mature, so manufacturing cost and supply reliability are more important than premium branding.

Lactose-free and patient-oriented products

A lactose-free bicalutamide tablet could be positioned for hospital formularies, specialty pharmacies, or patients with excipient preferences. The product would need a clear labeling and procurement advantage because the clinical need is narrower than for high-lactose oral medicines.

Bioavailability-enhanced products

A formulation that improves exposure under fasting conditions or reduces food dependence could support a differentiated 505(b)(2) strategy in the United States, subject to the selected regulatory pathway and clinical evidence. The development case is strongest if the product reduces pharmacokinetic variability or addresses a known administration limitation.

Supply-chain and regional manufacturing

Bicalutamide tablets require no cold chain and use broadly available excipients. Regional manufacturers can compete through:

• Local API sourcing.
• Dual-source excipient qualification.
• Shorter supply routes.
• Government procurement.
• Private-label production.
• Contract manufacturing for emerging markets.

The main barriers are API quality, regulatory compliance, bioequivalence, stability data, and reliable dissolution performance rather than complex delivery technology.

How does bicalutamide compare with newer prostate-cancer drugs?

Bicalutamide is commercially disadvantaged against newer androgen-receptor pathway inhibitors such as enzalutamide, apalutamide, and darolutamide in many treatment settings. Those products have stronger clinical differentiation, later patent cliffs, and larger branded revenue exposure. Bicalutamide remains relevant where cost, established use, combination with LHRH therapy, or formulary economics drive prescribing.

Product	Drug class	Formulation opportunity	Market position
Casodex	Nonsteroidal antiandrogen	Generic tablet, ODT, solubility enhancement	Mature, price-sensitive
Enzalutamide	Androgen-receptor inhibitor	Capsule/tablet and dose-optimization strategies	Higher-value branded and generic-transition market
Apalutamide	Androgen-receptor inhibitor	Tablet and combination development	Later-generation therapy
Darolutamide	Androgen-receptor inhibitor	Tablet and combination development	Differentiated safety and combination positioning

Bicalutamide’s long half-life and established once-daily use reduce the need for complex release technology. Its commercial advantage is low development risk and low manufacturing cost, not premium clinical positioning.

What generic launch risks exist for bicalutamide?

Generic launch risk is moderate to low for a standard immediate-release tablet, but several technical and commercial risks remain:

• Inability to match dissolution across pH conditions.
• API particle-size variability.
• Blend segregation at low dose loading.
• Excessive magnesium stearate lubrication.
• Film-coating defects affecting stability or appearance.
• Lactose or excipient compatibility issues.
• Narrow price spreads after multiple generic entrants.
• Declining demand where newer therapies replace bicalutamide.
• Limited reimbursement for differentiated formulations.
• Procurement concentration among large buyers.

The 150 mg monotherapy segment may be smaller than the 50 mg combination-use segment in some markets. A manufacturer should not assume that both strengths have equivalent volume or pricing.

What licensing opportunities are available?

Licensing opportunities are more likely to involve technology than the legacy Casodex brand. Relevant assets include:

• Proprietary bicalutamide solid forms.
• Nanocrystal or amorphous-dispersion platforms.
• ODT technologies.
• Lactose-free or low-weight tablet systems.
• Regional marketing rights.
• Contract manufacturing and private-label supply.
• Combination or co-packaging rights.
• Improved analytical and dissolution methods.

A licensing transaction is more defensible when the asset has one of three attributes: regulatory approval, demonstrated bioequivalence with manufacturing scale-up, or enforceable formulation IP. Unvalidated excipient concepts are more likely to support a development collaboration than a high-value royalty license.

Key Takeaways

• Casodex is an established bicalutamide immediate-release tablet with conventional excipients.
• The original product has lost its principal exclusivity protection, and generic competition is established.
• The strongest excipient opportunities are cost reduction, lactose-free delivery, dissolution enhancement, and orally disintegrating tablets.
• Modified release has limited rationale because bicalutamide is already dosed once daily and has a long half-life.
• New formulation patents may protect specific solid forms, particle sizes, polymers, processes, or combinations, but they are narrower and easier to design around than original composition-of-matter claims.
• Commercial returns depend more on manufacturing economics, supply reliability, regulatory execution, and payer access than on the legacy brand.
• A conventional generic tablet has the lowest development risk, while a solubility-enhanced or patient-oriented product offers greater differentiation but requires stronger regulatory and IP support.

FAQs

Can bicalutamide be formulated without lactose?

Yes. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, starch derivatives, and co-processed excipients can replace lactose, subject to formulation development, stability, dissolution, and bioequivalence requirements.

Is an amorphous solid dispersion commercially attractive for bicalutamide?

It can be attractive if it produces a meaningful exposure or administration benefit. The main risks are recrystallization, physical instability, scale-up complexity, and the possibility that improved dissolution will not create a clinically meaningful advantage.

Does bicalutamide need a controlled-release formulation?

Usually not. Its long terminal half-life and established once-daily dosing weaken the clinical case for controlled release.

Are Casodex excipients themselves patent-protected?

Common excipients such as lactose, povidone, sodium starch glycolate, magnesium stearate, hypromellose, and titanium dioxide are not proprietary to Casodex. A particular combination, ratio, manufacturing process, or delivery system may be protected by third-party or formulation patents.

Is a bicalutamide combination product likely to replace Casodex tablets?

A single-tablet combination faces clinical, regulatory, and dose-ratio constraints. Co-packaging may be more practical, but demand depends on treatment guidelines, oral availability of the companion therapy, reimbursement, and adherence evidence.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (2017). Casodex (bicalutamide) prescribing information. AstraZeneca Pharmaceuticals LP.

3. U.S. Food and Drug Administration. (2017). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/

4. National Library of Medicine. (n.d.). DailyMed: Bicalutamide tablet labeling. https://dailymed.nlm.nih.gov/

5. European Medicines Agency. (n.d.). Guideline on the investigation of bioequivalence. https://www.ema.europa.eu/